David, Thank you, I was on the testing calls and have reviewed the white paper. It does not address test data or test files in regards to quality assurance based methodologies and practices. It is this topic that my note was referring to....
Regards, Mark A Lott President HIPAA Testing, Inc. www.hipaatesting.com Office: 480-946-7200 Cell: 480-580-4415 Fax: 877-825-8309 "Advanced Testing and Certification of HIPAA Transaction Compliance" CONFIDENTIALITY NOTICE: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and/or privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message -----Original Message----- From: David Frenkel [mailto:[EMAIL PROTECTED]] Sent: Thursday, July 11, 2002 12:42 PM To: [EMAIL PROTECTED] Subject: RE: Testing for levels 3, 4, and 6 Mark, There will be 'final draft' of the updated Wedi testing white paper coming out tomorrow. You might take a look at it. Regards, David Frenkel Business Development GEFEG USA Global Leader in Ecommerce Tools www.gefeg.com 425-260-5030 -----Original Message----- From: Mark A Lott [mailto:[EMAIL PROTECTED]] Sent: Thursday, July 11, 2002 12:24 PM To: [EMAIL PROTECTED] Subject: RE: Testing for levels 3, 4, and 6 Greetings, Thoughts for the group..... I wanted to respond in more detail regarding what is among the largest issues facing the industry in relation to testing initiatives, namely 1)covered entities trying to decompose IG's to configure test conditions and 2)creating valid test data in EDI, instead of analyzing the problem from a true business perspective. The paradigm: Giving organizations the ability to continue testing applications with test data they are knowledgeable and proficient using (i.e. - UB92, NSF,ERA, HCFA, etc.) as opposed to trying to create EDI files from scratch, and not fully comprehending the correlation between proprietary data and EDI data. The scenario: A business stakeholder is asked for sign-off for HIPAA transaction compliance of their application system. The test files and test conditions were created in a language (EDI) and a process they are unfamiliar with and are unsure of what functionality was tested or not tested. How can they give sign-off? Certainly not just by examining reports stating that files passed an EDI compliance tool or trust that their translator must be working properly. How would they sign-off on any other system remediation project outside of HIPAA? A case study: Business Analysts and Test Analysts would have an easier and more intelligent test approach if they could create test conditions in proprietary formats and as a benefit they would also know the applicable test condition and expected result of such a test case. Thinking in terms of creating and running data according to "testing levels" is causing the need for additional staff, learning unfamiliar tools, working long hours, test case rework and unclear test conditions. This is creating an undue burden placed upon the business stakeholders and test teams to create in "unfamiliar" terms, the massive amounts of test data to validate that translators, applications systems and trading partners are in compliance. If you look at most any organization currently in the testing phase, you will find a team struggling to determine all the appropriate EDI test conditions and subsequent test data to prove systems are functioning properly and in compliance. We believe it is time for a new testing paradigm, especially as it relates to proper test data. One that will help covered entities to achieve true quality assurance and meet compliance regulations much faster than current methods and one that takes into consideration well-established quality assurance methodologies and techniques to determine test cases, test data and EDI compliance validation criteria. We are in process of building a consortium of quality assurance firms, consulting organizations and covered entities that truly understand the benefit with this new approach. This is an open invitation for quality assurance professionals and business stakeholders that would like to assist us in this new education initiative, EDI validation through rose-colored QA glasses... Mark A Lott President HIPAA Testing, Inc. www.hipaatesting.com Office: 480-946-7200 Cell: 480-580-4415 Fax: 877-825-8309 "Advanced Testing, Test Data and Certification of HIPAA Transaction Compliance" CONFIDENTIALITY NOTICE: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and/or privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message ********************************************************************** To be removed from this list, send a message to: [EMAIL PROTECTED] Please note that it may take up to 72 hours to process your request. ====================================================== The WEDI SNIP listserv to which you are subscribed is not moderated. The discussions on this listserv therefore represent the views of the individual participants, and do not necessarily represent the views of the WEDI Board of Directors nor WEDI SNIP. If you wish to receive an official opinion, post your question to the WEDI SNIP Issues Database at http://snip.wedi.org/tracking/. Posting of advertisements or other commercial use of this listserv is specifically prohibited. ********************************************************************** To be removed from this list, send a message to: [EMAIL PROTECTED] Please note that it may take up to 72 hours to process your request. ====================================================== The WEDI SNIP listserv to which you are subscribed is not moderated. The discussions on this listserv therefore represent the views of the individual participants, and do not necessarily represent the views of the WEDI Board of Directors nor WEDI SNIP. If you wish to receive an official opinion, post your question to the WEDI SNIP Issues Database at http://snip.wedi.org/tracking/. Posting of advertisements or other commercial use of this listserv is specifically prohibited. ********************************************************************** To be removed from this list, send a message to: [EMAIL PROTECTED] Please note that it may take up to 72 hours to process your request. ====================================================== The WEDI SNIP listserv to which you are subscribed is not moderated. The discussions on this listserv therefore represent the views of the individual participants, and do not necessarily represent the views of the WEDI Board of Directors nor WEDI SNIP. If you wish to receive an official opinion, post your question to the WEDI SNIP Issues Database at http://snip.wedi.org/tracking/. Posting of advertisements or other commercial use of this listserv is specifically prohibited.
